My First Medical Writing

SECTION EDITOR

Evguenia Alechine
ealechine@gmail.com

Editorial

In this release of *My First Medical Writing*, we spotlight another aspiring medical writer sharing insights on a topic of broad medical interest. Celina Galles, a PhD in Biological Sciences, brings over 15 years of expertise in molecular biology, microbiology, and recombinant protein expression. With a strong drive to advance biotechnological health solutions, she is passionate about using science communication to bridge the gap between research and real-world impact. Celina is keen to connect with peers in the medical writing community and contribute meaningfully to global scientific dialogue. This article reflects her dedication and enthusiasm – enjoy the read! **Evguenia**

Synbiotics: The power of virtuous interactions

Celina Galles
NOVA S. A. U., R&D Scientist
Cañada de Gómez, Argentina
celina.galles@gmail.com

doi: 10.56012/zflp8498

Synbiotics: The power of virtuous interactions

A growing tendency in microbiome-directed research is the combined use of probiotics (live microorganisms that confer health advantages when consumed) and specific non-digestible compounds that promote the growth of beneficial microorganisms (a.k.a., prebiotics), in what has been coined as synbiotics (yes, with an N, not an M).

An updated definition for synbiotics, carved by the International Scientific Association for Probiotics and Prebiotics, describes them as *a mixture comprising live microorganisms and substrates selectively utilised by host microorganisms that confer a health benefit to the host.*[1] In this way, the microbiota/substrate/host triangle is traced, supporting the logic that a health benefit or even the treatment of an illness can be achieved through the virtuous interaction of its three equally essential sides.

Synbiotic-based medical treatments could seriously reshape the future landscape of health-related processes such as immune modulation, nutrient absorption, and intestinal barrier function. But precisely what knowledge has been built on this subject? And what concrete applications can we expect to experience shortly?

Advances in synbiotics research and healthcare applications

In recent years, there has been a surge in research focusing on synbiotics. A quick literature search in PubMed on *synbiotics* will generate a list of more than 3,000 publications (https://pubmed.ncbi.nlm.nih.gov/?term=synbiotics). When studying the number of publications vs. time curve, one notices a steep and sustained yearly increase, starting to grow around the beginning of this century.

So, how can we start to explore this field in constant development?

A possible area to begin our exploration is that of antioxidants.[2] Antioxidant molecules can eliminate their toxic counterparts that bring about oxidative damage and stress and ultimately speed up ageing in cells. The body produces its antioxidants, but they may also be administered exogenously, as you surely recall from the advertisements of many commercial supplements. In our diet, antioxidants are present in raw fruits and vegetables and fermented foods. Science has recently discovered growing evidence of beneficial synbiotic effects on the oxidative damage pathways related to diseases such as Alzheimer's and diabetes, among others.[2]

The microbiota/substrate/host triangle is traced, supporting the logic that a health benefit or even the treatment of an illness can be achieved through the virtuous interaction of its three equally essential sides.

Synbiotics can also improve gut health. A high gut microbiota diversity has been correlated with low responsiveness to dietary/microbiota treatments. By providing the strain and its specific growth substrate together, the synbiotic approach guarantees more predictable outcomes for many of these treatments. Health claims have been made for synbiotics to treat metabolic syndrome, alleviate lactose intolerance, and decrease colon cancer risk.[3] Synbiotics could also prevent and treat Irritable Bowel Syndrome and Inflammatory Bowel Disease, improving mucosal structure and general epithelial barrier function.[3]

Synbiotics also benefit the gut-brain axis, a permanently active bidirectional communication highway that exchanges signals and influences physiological processes in both the gut and the brain. The production of neurotransmitters such as serotonin, dopamine, and GABA is influenced by gut microbiota; thus, synbiotics could indirectly affect mood regulation through these pathways.[4] Synbiotic modulation of the gut-brain axis can lead to improvements in central nervous system functions and help prevent or manage mental disorders, spanning depression, anxiety, and cognitive decline associated with neurodegenerative diseases like Alzheimer's.[3,5] Moreover, synbiotics may improve stress-related parameters by modulating the gut-brain axis.[6]



Synbiotic magic explained

What this mass of information clearly states is that synbiotics exert numerous and variable beneficial effects on human health, but exactly how and why does this happen? Translating this question into scientific jargon, one may ask what the underlying molecular mechanisms are that explain the observed effects of synbiotic treatments on so many varied health issues. It is worth mentioning that data and knowledge on synbiotics have accumulated over many years of research but have made major leaps with the recent expansion of metabolomic, proteomic, and sequencing technologies. Although I do not expect to answer this broad query in this brief article, we can venture to display the common players involved in synbiotics identified by scientists to date.

We first set our spotlight on a particular kind of lipids called Short-Chain Fatty Acids (SCFAs). Among the array of molecules present in living organisms, SCFAs are small in size and include the carboxylic acids acetate, butyrate, and propionate. And precisely, what is being promoted with certain synbiotic treatments is the production of these beneficial SCFAs in the gut by colonic bacteria, which can explain their positive consequences on health, involving anti-inflammatory effects and the regulation of gene expression.[3]

A second mechanism that can explain the positive action of synbiotics on health is the existence of communication routes between gut microflora and the immune system.[7,8] Probiotics secrete molecules that interact with gut immune and epithelial cells, allowing what may be conceived as a *cross-talk* or molecular conversation between them, that ultimately contributes to a robust immune system. In this way, a clear vertex constituted by two of the sides of the synbiotic triangle is identified in the microbiota-host interaction.

A third mechanism associated with synbiotics is related to their antimicrobial and anti-inflammatory effects. Synbiotics can produce antimicrobial substances and reduce inflammatory responses by regulating the production of cytokines and other immune mediators.[3,8]

Hold your (microbial) horses

Finally, we must discuss the immense challenges related to this new and exciting possibility of harnessing and strengthening human health and quality of life.

Given the huge, possibly infinite array of probiotic/prebiotic combinations, how can we be sure we are picking the right one to prevent or treat a given disease? And what about the third side of the triangle: The host? One could envisage an ideal, futuristic scenario where synbiotics are ordered *a la carte* or even specifically tailored for each disease and/or patient. Is this approach realistic? Can research and industry respond to this demand? If so, will this resource be available for the vast majority, or will it represent an exclusive, premium line of medicine?

Effective synbiotic clinical trials require careful consideration of dosage, controls, and strain-specific detection to demonstrate causality and ecological interactions, all of which elevate the complexity of the work being carried out.[9] While promising results exist from animal studies and human trials, more extensive clinical research is needed to establish these benefits across diverse populations.[9] Ecological constraints (e.g., competition with resident microbiota and substrate specificity) limit the efficacy of probiotics and prebiotics, contributing to inconsistent clinical outcomes. When it comes to the financial aspect, conducting extensive clinical trials to validate synbiotic health benefits is

expensive.[9] Using *in vitro* models can help reduce costs but may not fully replicate human conditions.[10]

These products also face concrete formulation challenges. The dosage of prebiotics can represent a hurdle: High doses are required for efficacy but may cause gastrointestinal side effects like bloating or flatulence, while lower doses risk reduced effectiveness.[11] Also related to this, many formulations prioritise cost and availability over functionality, with limited human trials showing consistent benefits. However, novel technologies such as microencapsulation may be the key to expanding the use of synbiotic treatments.[9] Microencapsulation protects probiotics and prebiotics from environmental factors such as heat, moisture, and oxygen. Consequently, thanks to this technology, the survival in the gut of probiotics and prebiotics is improved, their release in the gut is controlled and targeted, and the shelf life of the synbiotic products is extended.[9]

Regarding the commercialisation of synbiotics, although the global market for probiotics and prebiotics is growing, stringent regulatory steps still represent significant barriers. Regulatory requirements vary by region, so ensuring compliance across different markets can be tricky.[1] Also, compared to probiotics or prebiotics alone, consumer perception of synbiotics is less advanced, potentially affecting market demand.[12]

Concluding words

We invite you to consider this an open-ended story and remain alert to news on breakthroughs in the synbiotics field. As we continue to explore its vast potential, we look forward to future, insightful research that illuminates new, exciting pathways for human health and wellness.

References

1. Swanson KS, Gibson GR, Hutkins R, et al. The International Scientific Association for Probiotics and Prebiotics (ISAPP) consensus statement on the definition and scope of synbiotics. Nat Rev Gastroenterol Hepatol. 2020;17: 687–701. doi:10.1038/s41575-020-0344-2
2. Mounir M, Ibijbijen A, Farih K, et al. Synbiotics and their antioxidant properties, mechanisms, and benefits on human and animal health: A narrative review. Biomolecules. 2022;12(10):1443. doi:10.3390/biom12101443
3. Krumbeck JA, Walter J, Hutkins RW. Synbiotics for improved human health: Recent developments, Challenges, and Opportunities. Annu Rev Food Sci Technol. 2018;11(7):451–79. doi:10.1146/annurev-food-030117-012757
4. Loh JS, Mak WQ, Tan LKS, et al. Microbiota–gut–brain axis and its therapeutic applications in neurodegenerative diseases. Signal Transduct Target Ther. 2024;9(1):37. doi:10.1038/s41392-024-01743-1
5. Fekete M, Lehoczki A, Major D, et al. Exploring the influence of gut–brain axis modulation on cognitive health: A comprehensive review of prebiotics, probiotics, and symbiotics. Nutrients. 2024;16(6):789. doi:10.3390/nu16060789
6. Lalitsuradej E, Sirilun S, Sittiprapaporn P, et al. The effects of synbiotics administration on stress-related parameters in Thai subjects – A preliminary study. Foods. 2022;11(5):759. doi:10.3390/foods11050759
7. Williams LM, Stoodley IL, Berthon BS, et al. The effects of prebiotics, synbiotics, and short-chain fatty acids on respiratory tract infections and immune function: A systematic review and meta-analysis. Adv in Nutr. 2022;13(1):167–92. doi:10.1093/advances/nmab114
8. Li X, Hu S, Yin J, et al. Effect of synbiotic supplementation on immune parameters and gut microbiota in healthy adults: A double-blind randomized controlled trial. Gut Microbes. 2023;15(2):2247025. doi:10.1080/19490976.2023.2247025
9. Gomez Quintero DF, Kok CR, Hutkins R. The future of synbiotics: Rational formulation and design. Front Microbiol. 2022;13:919725. doi:10.3389/fmicb.2022.919725
10. Markowiak P, Śliżewska K. Effects of probiotics, prebiotics, and synbiotics on human health. Nutrients. 2017;9(9):1021. doi:10.3390/nu9091021
11. Rau S, Gregg A, Yaceczko S, Limketkai B. Prebiotics and probiotics for gastrointestinal disorders. Nutrients. 2024; 16(6):778. doi:10.3390/nu16060778
12. Chaturvedi S, Chakraborty S. Synbiotic foods: Significance, applications and acceptance. 1st ed. Abingdon (Oxon): CRC Press; 2024. Available from: https://www.routledge.com/Synbiotic-Foods-Significance-Applications-and-Acceptance/Chaturvedi-Chakraborty/p/book/9781032293370